Enhanced proliferation of the tumor cells that eventually results from the loss of TGF-β-induced growth arrest in PAR2-depleted/inhibited cells may also increase the cell’s sensitivity to gemcitabine chemotherapy. The gene discussed is F2RL1; the disease is neoplasm.